Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., explained in plain language.
-
New injection shows promise for stubborn sinus condition
Disease control CompletedThis study tested the long-term safety and effectiveness of an experimental injection called TQC2731 for adults with chronic sinusitis and nasal polyps. It involved 59 participants who had previously been in a related trial. The main goal was to see how safe the treatment was ove…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Disease control CompletedThis study tested an investigational drug called TQH3906 in 209 adults with moderate-to-severe plaque psoriasis. The main goal was to see if the drug safely reduces the severity of skin plaques and improves patients' quality of life over 12 weeks. Researchers measured how much sk…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New shot aims to tame seasonal sniffles
Symptom relief CompletedThis study tested whether a new injection called TQC2938 could help people with seasonal allergies feel better when added to their usual nasal spray. 136 adults with significant allergy symptoms during pollen season received either the injection or a placebo. Researchers measured…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Mar 31, 2026 12:11 UTC